San Diego, CA -- (SBWIRE) -- 06/14/2017 -- An investigation on behalf of investors, who currently hold shares of Albany Molecular Research, Inc. (NASDAQ:AMRI), was announced concerning whether the takeover of Albany Molecular Research, Inc. by The Carlyle Group and GTCR LLC for $21.75 per share is unfair to NASDAQ:AMRI stockholders.

Investors who purchased shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) and currently hold any of those NASDAQ:AMRI shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain officers and directors of Albany Molecular Research, Inc. breached their fiduciary duties owed to NASDAQ:AMRI investors in connection with the proposed acquisition.

On June 6, 2017, Albany Molecular Research, Inc. (NASDAQ:AMRI) announced it has signed an agreement to be acquired by affiliates of The Carlyle Group and GTCR LLC for $21.75 per share in cash.

However, the investigation concerns whether the offer is unfair to NASDAQ:AMRI stockholders. More specifically, the investigation concerns whether the Albany Molecular Research Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On June 9, 2017, NASDAQ:AMRI shares closed at $21.71 per share.

Those who are current investors in Albany Molecular Research, Inc. shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com